Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chumakov, Ilya ^a   Nabirotchkin, Serguei ^a   Cholet, Nathalie ^a   Milet, Aude ^a   Boucard, Aurelie ^a   Toulorge, Damien ^a   Pereira, Yannick ^a   Graudens, Esther ^a   Traore, Sory ^a   Foucquier, Julie ^a   Guedj, Mickael ^a   Vial, Emmanuel ^a   Callizot, Noelle ^b   Steinschneider, Remy ^c   Maurice, Tangui ^d,e,f   Bertrand, Viviane ^a   Scart Gres, Catherine ^a   Hajj, Rodolphe ^a   Cohen, Daniel ^a  

^a PHARNEXT   (France)

^b Department of Research and Development Neuro Sys SAS   (France)

^c Neuronexperts Medical North Faculty   (France)

^d UNIV MONTPELLIER   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f AMYLGEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID BETA-PROTEIN (25-35); AMYLOID PRECURSOR PROTEIN; BACLOFEN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; TAURINE;

ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG REPOSITIONING; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; BACLOFEN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG REPOSITIONING; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TAURINE;

EID: 84940564423     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07608     Document Type: Article

References (71)

1. Mullane, K., Williams, M. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond Biochem. Pharmacol. 85, 289-305 (2013).
2. Potter, P. E. Investigational medications for treatment of patients with Alzheimer disease. J. Am. Osteopath. Assoc. 110, S27-36 (2010).
3. Querfurth, H. W., LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med. 362, 329-44 (2010).
4. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201 (2008).
5. Iadecola, C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 120, 287-96 (2010).
6. Berk, C., Sabbagh, M. N. Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging 30, 783-92 (2013).
7. Pimentel-Coelho, P. M., Rivest, S. The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease. Eur. J. Neurosci. 35, 1917-37 (2012).
8. Paula-Lima, A. C., Brito-Moreira, J., Ferreira, S. T. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. J. Neurochem. 126, 191-202 (2013).
9. Rissman, R. A.,Mobley, W. C. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J. Neurochem. 117, 613-22 (2011).
10. Limon, A., Reyes-Ruiz, J. M. Miledi, R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U. S. A. 109, 10071-6 (2012).
11. Appleby, B. S., Cummings, J. L. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr. Top. Med. Chem. 13, 2306-27 (2013).
12. Dahchour, A. et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 82, 107-14 (1998).
13. Willard, S. S., Koochekpour, S. Glutamate, Glutamate Receptors, and Downstream Signaling Pathways. Int. J. Biol. Sci. 9, 948-959 (2013).
14. Revett, T. J., Baker, G. B., Jhamandas, J., Kar, S. Glutamate system, amyloid b peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J. Psychiatry Neurosci. 38, 6-23 (2013).
15. De Witte, P., Littleton, J., Parot, P., Koob, G. Neuroprotective and abstinencepromoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19, 517-37 (2005).
16. Chau, P., Stomberg, R., Fagerberg, A., Söderpalm, B., Ericson, M. Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study. Alcohol. Clin. Exp. Res. 34, 32-8 (2010).
17. Collard, C. D. et al. Neutrophil-derived glutamate regulates vascular endothelial barrier function. J. Biol. Chem. 277, 14801-11 (2002).
18. Van Den Eynden, J. et al. Glycine and glycine receptor signalling in non-neuronal cells. Front. Mol. Neurosci. 2, 9 (2009).
19. Shastry, S. et al. GABA receptors ameliorate Hcy-mediated integrin shedding and constrictive collagen remodeling in microvascular endothelial cells. Cell Biochem. Biophys. 45, 157-65 (2006).
20. LaFerla, F. M., Green, K. N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006320 (2012).
21. Callizot,N., Combes, M., Steinschneider, R. Poindron, P.Operational dissection of b-amyloid cytopathic effects on cultured neurons. J. Neurosci. Res. 91, 706-16 (2013).
22. Hayashi, S. et al. Alzheimer disease-associated peptide, amyloid beta40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler. Thromb. Vasc. Biol. 29, 1909-15 (2009).
23. Eckert, G. P. et al. Mitochondrial dysfunction-a pharmacological target in Alzheimer's disease. Mol. Neurobiol. 46, 136-50 (2012).
24. Pohanka, M. Alzheimer's disease and oxidative stress: a review. Curr. Med. Chem. 21, 356-64 (2013).
25. Esposito, Z. et al. Amyloid b, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track CNS Neurosci. Ther. 19, 549-55 (2013).
26. Avila, J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 580, 2922-7 (2006).
27. Amadoro, G. et al. Interaction between NH(2)-tau fragment and Ab in Alzheimer's disease mitochondria contributes to the synaptic deterioration. Neurobiol. Aging 33, 833.e1-25 (2012).
28. Chambon, C., Wegener, N., Gravius, A., Danysz, W. Behavioural and cellular effects of exogenous amyloid-b peptides in rodents. Behav. Brain Res. 225, 623-41 (2011).
29. Zussy, C. et al. Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid b fragment in rats. Am. J. Pathol. 179, 315-34 (2011).
30. Zussy, C. et al. Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-b peptide injection in rats. PLoS One 8, e53117 (2013).
31. Balducci, C., Forloni, G. In Vivo Application of Beta Amyloid Oligomers: a Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches. Curr. Pharm. Des. 20, 2491-505 (2013).
32. Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., Kosenko, E. A. Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp. Neurol. 221, 26-37 (2010).
33. Logue, S. F., Paylor, R., Wehner, J. M. Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task. Behav. Neurosci. 111, 104-13 (1997).
34. Antunes, M., Biala, G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn. Process. 13, 93-110 (2012).
35. Lalonde, R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev. 26, 91-104 (2002).
36. Rudy, J. W., Huff, N. C., Matus-Amat, P. Understanding contextual fear conditioning: insights from a two-process model. Neurosci. Biobehav. Rev. 28, 675-85 (2004).
37. Marchetti, C.,Marie, H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models Rev. Neurosci. 22, 373-402 (2011).
38. Cai, Z., Zhao, B., Ratka, A. Oxidative stress and b-amyloid protein in Alzheimer's disease. Neuromolecular Med. 13, 223-50 (2011).
39. Strosznajder, J. B., Czapski, G. a., Adamczyk, A., Strosznajder, R. P. Poly(ADPribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol. Neurobiol. 46, 78-84 (2012).
40. Heneka,M. T., O'Banion, M. K., Terwel, D. Kummer, M. P. Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm. 117, 919-47 (2010).
41. Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C.-Y., Rodriguez, J. J. Astrocytes in Alzheimer's disease. Neurotherapeutics 7, 399-412 (2010).
42. Palop, J. J., Mucke, L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-8 (2010).
43. Meunier, J., Villard, V., Givalois, L., Maurice, T. The c-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Ab1-42 seeding and shortterm memory deficits in the Ab25-35 mouse model of Alzheimer's disease. Eur. J. Pharmacol. 698, 193-9 (2013).
44. Kimura, N., Takahashi, M., Tashiro, T., Terao, K. Amyloid beta up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid beta-related neuritic degeneration. J. Neurosci. Res. 84, 782-9 (2006).
45. Frautschy, S. A., Cole, G. M. Why pleiotropic interventions are needed for Alzheimer's disease. Mol. Neurobiol. 41, 392-409 (2010).
46. Ainsworth, C. Networking for new drugs. Nat. Med. 17, 1166-8 (2011).
47. Ulrich,D. Bettler, B.GABA(B) receptors: synaptic functions andmechanisms of diversity. Curr. Opin. Neurobiol. 17, 298-303 (2007).
48. Tu,H. et al. GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. J. Neurosci. 30, 749-59 (2010).
49. Sharp, C. D. et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am. J. Physiol. Heart Circ. Physiol. 285, H2592-8 (2003).
50. Gillard, S. E., Tzaferis, J., Tsui, H.-C. T., Kingston, A. E. Expression of metabotropic glutamate receptors in rat meningeal and brain microvasculature and choroid plexus. J. Comp. Neurol. 461, 317-32 (2003).
51. Mason, B. J. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J. Clin. Psychiatry 62 Suppl 2, 42-8 (2001).
52. Spanagel, R. et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 39, 783-91 (2014).
53. Rammes, G. et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40, 749-60 (2001).
54. Popp, R. L., Lovinger, D. M. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur. J. Pharmacol. 394, 221-31 (2000).
55. Harris, B. R. et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res. 26, 1779-93 (2002).
56. Lee, H. et al. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. ActaNeuropathol. 107, 365-71 (2004).
57. Caraci, F. et al. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 an. Mol. Pharmacol. 79, 618-26 (2011).
58. Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer ab oligomer bound to cellular prion protein. Neuron 79, 887-902 (2013).
59. Hamilton, A., Esseltine, J. L., DeVries, R. a., Cregan, S. P., Ferguson, S. S. G. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol. Brain 7, 40 (2014).
60. Westmark, C. J.,Malter, J. S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5, e52 (2007).
61. Kim, S. H. et al. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J. Neurosci. 30, 3870-5 (2010).
62. Danglot, L., Rostaing, P., Triller, A., Bessis, A. Morphologically identified glycinergic synapses in the hippocampus. Mol. Cell. Neurosci. 27, 394-403 (2004).
63. Ryu, J. K., McLarnon, J. G. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell. Mol. Med. 13, 2911-25 (2009).
64. Zahs, K. R., Ashe, K. H. "Too much good news"-are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease Trends Neurosci. 33, 381-9 (2010).
65. Havas, D. et al. A longitudinal study of behavioral deficits in an AbPP transgenic mouse model of Alzheimer's disease. J. Alzheimers. Dis. 25, 231-43 (2011).
66. Necula, M., Kayed, R., Milton, S., Glabe, C. G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311-24 (2007).
67. Morris, R. G. Spatial Localization Does Not Require the Presence of Local Cues. Learn. Motiv. 12, 239-260 (1981).
68. Maurice, T., Lockhart, B. P., Privat, a. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706, 181-93 (1996).
69. Villard, V. et al. Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice. Neuropsychopharmacology 34, 1552-66 (2009).
70. Tallarida, R. J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319, 1-7 (2006).
71. Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 3, 285-90 (1953).